entrectinib

Showing 2 posts of 2 posts found.

roche__tree

Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents

May 17, 2019
Medical Communications, Research and Development Cancer, Roche, entrectinib, pharma

Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …

Roche’s entrectinib shrinks lung tumours with two-year response duration

September 25, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib

Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …

The Gateway to Local Adoption Series

Latest content